recent
year
sever
paramyxovirus
emerg
infect
human
includ
previous
unidentifi
zoonos
hendra
nipah
viru
henipaviru
hnv
zoonos
first
identifi
caus
death
anim
human
australia
malaysia
respect
paramyxovirus
menangl
viru
tioman
viru
human
metapneumoviru
avian
less
morbid
human
also
recent
identifi
although
paramyxovirida
famili
virus
previous
recogn
biomed
veterinarili
import
recent
emerg
paramyxovirus
increas
attent
famili
antivir
drug
design
target
specif
import
determin
viralcel
life
cycl
therefor
identifi
understand
mechanist
underpin
viral
entri
replic
assembl
bud
critic
develop
antivir
therapeut
agent
review
focus
molecular
mechan
discov
antivir
strategi
pursu
recent
year
emerg
paramyxovirus
concentr
viral
entri
exit
mechan
global
human
encroach
nativ
wildlif
habitat
like
continu
caus
increas
emerg
zoonot
viral
diseas
recent
year
member
paramyxovirida
viral
famili
caus
deadliest
emerg
zoonos
paramyxovirida
famili
compris
import
old
new
human
anim
viral
pathogen
nipah
niv
hendra
hev
virus
make
new
henipaviru
genu
within
famili
henipavirus
first
appear
australia
malaysia
singapor
caus
epidem
concern
nation
intern
author
due
high
mortal
morbid
rate
affect
anim
human
paramyxovirus
host
rang
narrow
cross
speci
transmiss
event
rare
addit
niv
spread
effici
caus
morbid
econom
import
livestock
due
high
virul
absenc
therapeut
vaccin
henipavirus
classifi
biosafeti
level
pathogen
niv
classifi
categori
c
prioriti
pathogen
niaid
biodefens
research
agenda
bioand
agroterror
potenti
characterist
henipavirus
underscor
need
research
treatment
develop
peril
pathogen
numer
studi
uncov
determin
import
variou
step
paramyxoviru
life
cycl
step
repres
potenti
target
develop
antivir
drug
fig
among
emerg
paramyxovirus
henipavirus
studi
extens
rel
high
morbid
rate
gener
viru
bind
host
cell
receptor
paramyxovirus
requir
cooper
two
separ
attach
fusion
transmembran
glycoprotein
review
howev
attach
glycoprotein
activ
fusion
protein
fusion
protein
sens
right
time
place
carri
hostvir
membran
fusion
function
still
matter
intens
investig
regul
molecular
choreographi
lead
product
membran
fusion
provid
fertil
area
develop
therapeut
thwart
process
develop
antivir
therapeut
agent
facilit
elucid
molecular
mechan
underli
variou
step
viral
life
cycl
exampl
insight
life
cycl
led
approv
antiretrovir
drug
target
distinct
step
coreceptor
antagonist
fusion
inhibitor
target
viral
entri
nucleosid
nonnucleosid
inhibitor
target
viral
revers
transcriptas
integras
inhibitor
target
integr
proteas
inhibitor
target
viral
matur
review
emerg
paramyxovirus
recent
discoveri
molecular
mechan
underpin
sever
step
life
cycl
includ
host
receptor
usag
membran
fusion
viral
entri
viral
replic
interferon
respons
assembl
bud
promis
shed
light
develop
antivir
therapeut
drug
research
advanc
antivir
therapeut
strategi
discuss
heavier
concentr
viral
entri
assembl
step
carri
f
g
viral
protein
molecular
mechan
antivir
approach
target
function
nonstructur
paramyxoviru
protein
particularli
gene
product
p
v
c
w
previous
review
greater
detail
paramyxoviru
attach
protein
type
ii
transmembran
protein
surfac
virion
mediat
attach
viru
cell
surfac
receptor
attach
protein
receptor
interact
play
import
role
determin
cell
tropism
sever
conserv
featur
among
known
paramyxoviru
attach
protein
g
h
hn
contain
head
domain
link
viral
membran
stalk
domain
cytoplasm
tail
intravir
intracellular
protein
express
cell
surfac
fig
globular
head
hevg
nivg
hnvg
structur
common
head
domain
multipl
paramyxoviru
attach
protein
oligomer
structur
hnvg
dimer
dimer
also
thought
resembl
attach
glycoprotein
paramyxovirina
like
fine
balanc
stoichiometri
requir
optim
fusion
endogen
lectin
like
see
caus
inappropri
oligomer
henipaviru
envelop
protein
detriment
fusion
process
emerg
paramyxoviru
receptorsth
host
receptor
menangl
viru
tioman
viru
human
metapneumoviru
beilong
j
virus
consid
emerg
paramyxovirus
lower
morbid
human
unknown
review
contrast
receptor
henipavirus
discov
respect
transmembran
protein
receptortyrosin
kinas
interact
endogen
receptor
oppos
cell
play
critic
role
cellcel
signal
particularli
angiogen
neuron
develop
distribut
consist
respiratori
neurolog
symptom
henipaviru
infect
highli
express
endotheli
cell
line
microvasculatur
neuron
cn
express
brain
stem
entri
may
account
brain
stem
dysfunct
ultim
caus
death
niv
enceph
identif
niv
hev
receptor
greatli
facilit
ration
develop
strategi
therapeut
block
virusreceptor
bind
mechan
fusion
trigger
attach
proteinwith
except
attach
protein
paramyxovirus
essenti
viral
entri
fig
even
respiratori
syncyti
viru
whose
attach
protein
requir
membran
fusion
fusion
enhanc
presenc
attach
glycoprotein
interestingli
hmpv
membran
fusion
sometim
replic
enhanc
presenc
attach
protein
review
thu
specif
role
attach
protein
promot
viral
entri
subject
intens
studi
review
sever
studi
variou
paramyxovirus
implic
role
attach
glycoprotein
stalk
domain
interact
trigger
fusion
glycoprotein
ultim
protein
mediat
membran
fusion
biochem
biophys
studi
suggest
receptorinduc
conform
chang
nivg
involv
critic
residu
base
nivg
head
domain
presenc
intact
stalk
domain
import
alloster
trigger
fusion
protein
although
dramat
differ
found
apoand
receptorbound
structur
nivg
stalk
domain
appar
structur
perhap
presenc
stalk
allow
proper
disassembl
higher
order
oligom
upon
receptor
bind
may
lead
exposur
neoepitop
function
trigger
fusion
protein
although
specif
hnvg
trigger
fusion
protein
beyond
scope
review
like
trigger
process
fine
tune
therefor
vulner
disrupt
better
understand
trigger
process
may
lead
therapeut
target
conserv
featur
may
limit
develop
resist
exampl
antihnvg
antibodi
recogn
conserv
neoepitop
expos
receptor
bind
may
good
candid
passiv
immun
strategi
antivir
strategi
target
attach
proteinther
number
mab
produc
nivg
hevg
rang
vitro
neutral
activ
ngml
one
human
mab
engag
receptor
bind
site
niv
hev
g
appear
protect
lethal
challeng
ferret
model
administ
intraven
hour
postinfect
hour
preinfect
differ
could
due
rel
low
serum
stabil
administ
intraven
nevertheless
bode
well
develop
postexposur
therapeut
resourcesuffici
set
comparison
palivizumab
medimmun
inc
fda
approv
mab
therapeut
target
fusion
protein
human
respiratori
syncyti
viru
hrsv
vitro
ngml
administ
monthli
hrsv
prophylaxi
via
intramuscular
inject
still
maintain
serum
concentr
vitro
patient
would
interest
see
im
inject
increas
effect
halflif
vivo
solubl
solubl
henipaviru
g
hnvg
protein
also
shown
block
viru
entri
cellcel
fusion
although
like
interfer
ephrinb
function
antigen
hnvg
limit
practic
util
molecul
antivir
howev
structur
bound
hnvg
complex
show
larg
proteinprotein
interfac
also
reveal
lockandkey
bind
pocket
may
target
small
molecul
therapeut
exampl
gh
loop
interact
differ
hnvg
suggest
druggabl
pocket
disrupt
interact
specif
like
caveat
approach
small
molecul
design
fit
bind
pocket
specif
might
still
abl
overcom
strong
avid
oligomer
interact
exampl
bind
nivg
subnanomolar
affin
kd
nm
suggest
drug
would
bind
picomolar
concentr
slow
offrat
compet
interact
fusion
glycoprotein
synthes
trimer
precursor
activ
proteas
cleavag
metast
prefus
conform
pois
enabl
membran
fusion
fig
cleavag
gener
new
hydrophob
nterminu
fusion
peptid
buri
metast
prefus
f
conform
upon
attach
proteinreceptor
bind
fusion
cascad
trigger
fusion
peptid
f
harpoon
target
cell
membran
prehairpin
intermedi
conform
fig
two
helic
region
present
prehairpin
intermedi
high
affin
coalesc
form
sixhelix
bundl
bring
viral
target
cell
membran
togeth
close
apposit
allow
viraltargetcel
membran
fusion
viral
entri
matur
fusion
proteinhowev
import
differ
viral
entri
membran
fusion
mechan
carri
f
protein
highlight
emerg
paramyxovirus
first
mani
paramyxovir
f
protein
cleav
twice
furinlik
cellular
proteas
transport
tran
golgi
network
hmpv
sendai
viru
fs
cleav
tissuespecif
extracellular
proteas
miniplasmin
tryptas
clara
cell
surfac
henipaviru
f
cleav
cathepsinl
upon
endocytosi
specif
inhibit
proteas
antivir
compound
could
envis
exampl
lack
acut
lethal
phenotyp
cathepsinl
knockout
mice
suggest
shortterm
inhibit
cathepsinl
context
highli
pathogen
viru
infect
may
clinic
viabl
option
recent
smallmolecul
oxocarbaz
specif
inhibitor
cathepsin
l
report
effect
ebola
sar
virus
subnanomolar
concentr
vitro
although
ebola
sar
virus
directli
requir
cathepsin
l
cleavag
viral
entri
compound
could
also
prove
use
treat
henipaviru
infect
prevent
gener
matur
f
howev
past
vitro
vs
vivo
discrep
drug
indirectli
inhibit
cathepsinl
cleavag
observ
chloroquin
normal
use
treat
malaria
shown
inhibit
pseudotyp
niv
entri
presum
inhibit
endosom
acidif
indirectli
cathepsinl
activ
howev
chloroquin
treatment
found
prevent
niv
infect
diseas
ferret
combin
chloroquin
ribavirin
treatment
prevent
death
hamster
model
niv
hev
infect
vitro
vs
vivo
discrep
suggest
need
improv
understand
role
endocytosi
cathepsinl
cleavag
henipaviru
infect
nglycan
henipaviru
f
characterist
emerg
paramyxovir
f
protein
atyp
use
nglycan
paramyxoviru
f
protein
specif
nglycan
either
necessari
proper
protein
fold
andor
nglycan
remov
deleteri
fusion
process
surprisingli
remov
specif
individu
multipl
nglycan
nivand
hevf
result
mark
hyperfusogen
manifest
fusion
viral
entri
assay
howev
nglycan
remov
also
increas
sensit
nivf
antibodi
neutral
thu
appear
nglycan
henipaviru
f
kept
least
partial
serv
shield
antibodi
neutral
nivf
nglycan
also
found
abl
mediat
bind
innat
immun
lectin
mani
function
bind
specif
galactosecontain
carbohydr
surfac
mammalian
cell
pathogen
review
inhibit
nivmedi
cellcel
fusion
syncytia
format
hallmark
niv
pathogen
interestingli
individu
nglycan
nivf
whose
remov
result
highest
level
hyperfusogen
also
gave
rise
optim
nglycan
moieti
mediat
bind
nivf
endogen
level
endotheli
cell
suffici
inhibit
niv
envelop
mediat
syncytia
bind
nglycan
nivf
inhibit
matur
mobil
trigger
f
protein
unlik
develop
antivir
therapeut
pleotrop
effect
report
shed
light
innat
immun
defens
base
recognit
pathogen
associ
molecular
pattern
pamp
furthermor
singl
nucleotid
polymorph
identifi
genom
locu
rais
intrigu
possibl
genet
variabl
locu
may
contribut
rang
pathophysiolog
seen
henipaviru
infect
block
membran
fusion
cascadeblock
viral
entri
trap
one
fusion
protein
intermedi
membran
fusion
cascad
therapeut
approach
pursu
util
class
fusion
protein
envelop
virus
exampl
enfuvirtid
sifuvirtid
analog
peptid
mimic
ctermin
heptadrepeat
region
class
fusion
protein
approv
treatment
review
sinc
paramyxovir
f
protein
undergo
equival
class
fusion
protein
conform
chang
includ
prehairpin
intermedi
format
paramyxoviru
aka
hrc
peptid
use
trap
prehairpin
intermedi
fig
although
ntermin
regionmimick
peptid
also
inhibit
fusion
gener
less
effici
inhibitor
even
artifici
trimer
mimic
trimer
core
henipavirus
peptid
shown
inhibit
cellcel
membran
fusion
viral
entri
pseudotyp
viral
system
nanomolar
concentr
surprisingli
higher
level
inhibit
hev
fusion
observ
use
human
f
vs
hevf
deriv
peptid
although
mechan
phenomenon
unclear
addit
second
gener
cap
pegyl
peptid
result
increas
solubl
water
stabil
synthesi
yield
possibl
use
antivir
agent
vivo
anoth
strategi
increas
peptid
inhibit
efficaci
addit
cholesterol
peptid
cterminu
approach
like
bring
peptid
close
proxim
membran
site
action
fusion
occur
reduc
ic
deriv
peptid
pseudotyp
hev
niv
infect
nm
near
nm
howev
ic
inhibit
live
hev
niv
virus
vitro
close
nm
rel
larg
amount
peptid
mgkg
need
achiev
less
surviv
hamster
infect
niv
use
simultan
previou
niv
infect
like
larg
peptid
amount
need
order
effici
coat
surfac
target
cell
host
anoth
approach
inhibit
membran
fusion
block
fusion
protein
conform
chang
requir
fusion
cascad
use
mab
two
antinivf
antibodi
report
neutral
niv
hev
vitro
ng
hamster
model
although
bind
epitop
antibodi
character
crossreact
hev
desir
suggest
may
target
conserv
region
hnvf
may
limit
gener
escap
variant
moreov
antibodi
bind
conform
epitop
critic
membran
fusion
highli
desir
sinc
mutat
annul
mab
bind
need
conform
chang
would
rel
rare
conform
mab
henipavirus
prefer
bind
hyperor
hypofusogen
mutant
report
neutral
activ
bind
epitop
shown
quinolon
deriv
design
base
structur
similar
among
paramyxoviru
f
protein
bind
motif
test
inhibit
nivand
measl
virusinduc
cell
fusion
two
compound
test
moder
activ
inhibitor
nivinduc
cellcel
fusion
niv
infectioninduc
syncytia
ec
compound
also
show
cytotox
vero
cell
cc
use
mtt
test
result
select
index
compound
lowest
toxic
si
rel
poor
lead
compound
may
improv
structur
activ
relat
sar
analysi
mutant
caus
resist
peptid
bind
detect
hiv
similar
mutant
may
occur
use
smallmolecul
inhibitor
target
interact
proteinparamyxovir
matrix
protein
structur
protein
directli
underli
viral
envelop
import
assembl
bud
viral
particl
infecti
paramyxovir
particl
form
structur
viral
compon
assembl
select
site
cell
membran
protein
known
organ
assembl
process
posit
protein
underneath
cellular
plasma
membran
allow
interact
ribonucleoprotein
rna
genom
bound
nucleocapsid
n
np
protein
viral
glycoprotein
via
cytoplasm
tail
recent
atom
structur
paramyxoviru
human
respiratori
syncyti
viru
protein
solv
shown
contain
two
betasheetrich
domain
join
short
unstructur
linker
structur
similar
filoviru
ebola
join
domain
share
extens
posit
charg
surfac
like
bind
negativelycharg
membran
phospholipid
head
group
mani
paramyxovirus
transient
express
protein
alon
without
express
viral
protein
suffici
form
releas
virallik
particl
vlp
case
sendai
viru
ndv
measl
viru
niv
howev
case
mdepend
vlp
product
enhanc
presenc
viral
protein
glycoprotein
nucleocapsid
protein
c
protein
review
antivir
msinc
protein
critic
paramyxovir
assembl
bud
antivir
agent
target
import
aspect
mdirect
assembl
bud
envis
exampl
inhibit
ndv
replic
target
two
distinct
site
gene
use
rnai
recent
report
addit
simian
viru
proteasom
inhibitor
express
dominantneg
atpas
block
bud
like
involv
ubiquitinproteasom
pathway
bud
niv
recent
studi
show
ubiquitinregul
nuclearcytoplasm
traffick
nivm
import
viral
bud
therefor
compound
block
ubiquitin
enzym
deplet
free
ubiquitin
cell
proteasom
inhibitor
preferenti
block
nuclear
import
export
nivm
could
potenti
antihenipaviru
candid
fig
inde
bortezomib
fdaapprov
proteasom
inhibitor
use
treat
multipl
myeloma
reduc
viral
titer
significantli
ic
nm
less
achiev
plasma
concentr
human
thu
fdaapprov
agent
potenti
evalu
offlabel
use
henipaviru
treatment
understand
cellular
compon
play
import
role
viral
assembl
releas
also
aid
discoveri
novel
drug
target
step
life
cycl
emerg
paramyxovirus
interferon
ifn
part
innat
immun
system
constitut
one
first
line
defens
viral
pathogen
mammal
earli
virushost
battl
determin
establish
infect
p
gene
encod
p
c
v
w
protein
subfamili
paramyxovirina
p
gene
product
gener
antiifn
activ
see
part
p
gene
antivir
activ
due
effect
limit
extent
viral
genom
replic
sinc
aberr
transcript
activ
retino
acid
induc
gene
rigi
rna
helicas
pathway
activ
interferon
product
exampl
simian
viru
p
protein
sendai
c
protein
measl
c
protein
jviru
beilong
viru
c
protein
c
protein
henipaviru
c
v
w
protein
shown
inhibit
viral
genom
replic
addit
henipaviru
p
gene
protein
shown
inhibit
ifn
signal
pathway
review
sinc
restor
interferon
respons
success
treatment
cancer
autoimmun
infecti
diseas
type
approach
may
also
suitabl
emerg
paramyxoviru
infect
one
studi
show
interferon
induc
poli
poli
mismatch
doublestrand
rna
prevent
death
niv
infect
hamster
model
ampligen
also
observ
effect
sarscoronaviru
infect
mous
model
shown
posit
effect
hiv
patient
congruent
studi
find
niv
hev
replic
effici
vero
cell
defect
ifn
respons
compar
cell
line
therefor
stimul
interferon
product
seem
promis
treatment
henipaviru
infect
current
antivir
drug
target
differ
viral
agent
host
specif
viral
protein
moieti
import
viral
entri
replic
assembl
bud
etc
confer
specif
infect
cell
howev
target
specif
viral
protein
moieti
alway
best
solut
viral
resist
mutagenesi
common
target
singl
even
multipl
viral
protein
thu
strategi
target
nonprotein
determin
import
step
viral
life
cycl
particularli
broad
assort
virus
highli
desir
exampl
broadspectrum
compound
target
viral
membran
fluiditi
requir
viral
entri
exit
rna
replic
recent
explor
viral
membran
inhibitorrec
highthroughput
screen
assay
base
nivvsvpseudotyp
viral
entri
inhibit
identifi
small
molecul
intercal
irrevers
damag
viral
membran
cellular
membran
low
micromolar
concentr
studi
lipid
biosynthesi
inhibitor
indic
exploit
differ
static
viral
membran
biogen
cellular
membran
repar
capac
rhodanin
deriv
effect
numer
envelop
virus
nonenvelop
virus
show
overt
toxic
vitro
vivo
si
inactiv
virion
leav
envelop
protein
function
intact
inhibit
postbind
prefus
step
thu
may
repres
new
class
broadspectrum
antivir
target
physiolog
rather
physic
differ
viral
cellular
lipid
membran
potenti
mechan
action
would
disrupt
proper
balanc
satur
unsatur
phospholipid
requir
posit
neg
membran
curvatur
transit
fusion
process
review
elucid
exact
mechan
effectu
membran
damag
activ
shed
light
whether
differ
viral
cellular
membran
exploit
chemotyp
help
refin
medicin
chemistri
effort
improv
bioavail
vivo
efficaci
cation
compoundsin
anoth
studi
highthroughput
screen
base
liveviru
infect
identifi
three
compound
unsuit
intern
administr
possibl
suitabl
topic
applic
three
compound
gliotoxin
gentian
violet
brilliant
green
previous
use
antibacteri
antifung
agent
show
antivir
activ
niv
hev
vsv
addit
gliotoxin
inhibit
influenza
suggest
broadspectrum
activ
compound
although
mode
action
cation
compound
known
propos
directli
bind
inhibit
viral
membran
recent
studi
test
licens
pharmaceut
henipaviru
replic
vitro
compound
releas
intracellular
calcium
store
calcium
chelat
well
calcium
channel
calmodulin
antagonist
inhibit
henipaviru
replic
micromolar
rang
howev
mechan
link
calcium
influx
henipaviru
replic
unknown
vivo
assay
report
ribavirinribavirin
broadspectrum
antivir
use
particularli
rsv
hepat
c
also
use
rna
virus
avail
treatment
purin
nucleosid
analog
although
exact
mechan
inhibit
viral
replic
complet
understood
known
ribavirin
interfer
rna
metabol
requir
viru
replic
emerg
paramyxovirus
variou
result
ribavirin
report
first
niv
outbreak
malaysia
reduct
mortal
human
report
addit
sever
studi
report
inhibit
henipaviru
replic
ribavirin
vitro
howev
vivo
studi
carri
anim
model
yield
promis
result
ribavirin
ribavirin
inabl
cross
bloodbrain
barrier
bbb
may
account
inadequaci
vivo
studi
previous
shown
ribavirin
effect
brain
administ
intracrani
intraperitoni
hamster
model
malaysian
epidem
effect
ribavirin
lateonset
niv
enceph
report
addit
complex
molecular
mechan
inhibit
viral
replic
ribavirin
induct
error
catastroph
deplet
intracellular
gtp
pool
may
allow
rapid
design
potent
analogu
review
chloroquinechloroquin
use
treatment
pathogen
requir
endosom
acidif
malaria
phdepend
virus
sinc
henipavirus
requir
endosom
cleavag
f
protein
surpris
chloroquin
found
potenti
inhibitor
niv
infect
vitro
howev
oral
administr
chloroquin
protect
ferret
lethal
niv
infect
even
though
effect
serum
chloroquin
concentr
achiev
periton
administr
chloroquin
alon
combin
ribavirin
protect
hamster
lethal
niv
hev
challeng
ribavirin
lack
vivo
success
chloroquin
may
due
inabl
cross
bbb
inadequ
tissu
distribut
well
effect
immun
system
may
favor
host
vitro
vs
vivo
discrep
choroquin
treatment
result
also
report
influenza
sar
hiv
chikungunya
virus
sirnaan
altern
way
inhibit
viral
gene
express
use
small
interf
rna
sirna
one
recent
studi
sirna
molecul
direct
l
n
gene
test
minigenom
live
henipaviru
replic
vitro
sirna
effect
minigenom
live
viru
replic
effect
minigenom
replic
other
neither
addit
sirna
target
conserv
genom
sequenc
instanc
p
v
w
propos
although
somewhat
promis
one
disadvantag
approach
need
gene
therapybas
sirna
deliveri
method
might
readili
avail
type
entri
pathway
niv
necessit
phosphoryl
cytoplasm
domain
nivg
attach
although
known
whether
major
pathway
util
niv
entri
drug
affect
macropinocytosi
except
chloroquin
affect
niv
entri
cellcel
fusion
two
strongest
inhibitor
niv
entri
latrunculin
amilorid
analogu
eipa
nethylnisopropyl
amilorid
first
one
like
hazard
vivo
eipa
commonli
use
antihypertens
agent
evalu
vivo
efficaci
anim
model
henipaviru
infect
favipiravir
favipiravir
compound
promis
broadspectrum
antivir
activ
host
enzym
metabol
precursor
ribofuranosyltriphosph
deriv
select
inhibit
viral
rnadepend
rna
polymeras
reason
fulli
understood
review
importantli
inhibit
host
dna
rna
synthesi
cytotox
mammalian
cell
vivo
experi
influenza
viru
arenaviru
bunyavirus
west
nile
viru
yellow
fever
viru
footandmouthdiseas
viru
shown
one
follow
result
protect
death
reduct
viral
load
limit
symptom
addit
protect
effect
observ
administ
day
postviru
inocul
see
although
pathogen
paramyxovirus
vitro
succept
respiratori
syncyti
viru
observ
suggest
favipiravir
may
serv
antivir
emerg
paramyxovirus
variou
antivir
strategi
discuss
review
summar
tabl
gener
better
understand
structur
function
viral
host
protein
involv
viral
life
cycl
fig
aid
develop
new
antivir
therapeut
addit
anim
model
experi
examin
potenti
antivir
born
vitro
studi
describ
import
exampl
compound
success
cross
bbb
emerg
viru
entri
mechan
explor
greater
detail
assembl
bud
mechan
progress
elucid
late
step
viral
life
cycl
imper
prompt
antivir
discoveri
character
emerg
paramyxovirus
facilit
use
pseudotyp
revers
genet
viral
system
attach
membran
fusion
step
necessari
viral
entri
step
fig
depict
greater
detail
three
major
stage
f
depict
prefus
prehairpin
intermedi
postfus
form
bind
nivg
initi
conform
cascad
f
b
f
trigger
form
prehairpin
intermedi
phi
fusion
peptid
harpoon
host
cell
membran
phi
captur
peptid
mimic
niv
orang
stripe
cylind
region
green
stripe
cylind
bind
f
region
respect
c
region
phi
coalesc
form
sixhelix
bundl
conform
bring
viral
cell
membran
togeth
facilit
viralhost
membran
fusion
viral
entri
figur
bottom
henipaviru
genom
rna
repres
orient
ribbon
structur
monom
nivg
blue
head
domain
pdb
code
interact
receptor
red
drawn
use
pymol
wwwpymolorg
model
align
monom
monom
hemaglutininneuraminidas
dimer
pdb
code
similarli
second
monom
shown
gray
accord
model
flexibl
region
nivg
ectodomain
green
orang
may
interact
region
anoth
monom
may
involv
receptorinduc
g
mediat
nivf
trigger
e
represent
structur
nivf
protein
model
use
crystal
structur
pdb
code
phyre
threde
program
perform
f
represent
trimer
nivf
monom
e
also
model
use
crystal
structur
